2008-03-19 23:40:06 -

www.researchandmarkets.com - Research and Markets (www.researchandmarkets.com/reports/c86315) has announced the addition of "Peru Pharmaceuticals and Healthcare Report Q1 2008" to their offering.

The Peru Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Peru's pharmaceuticals and healthcare industry.

Peru's pharmaceutical market remains small in relative terms - standing at an estimated

US$666mn in 2007. Per capita drug expenditure is just US$23.1 due to a preference for cheap, non-equivalent branded generics called 'similares'. The market is forecast to reach US$850mn by 2012, representing a CAGR of just 5%. We expect the generics market in particular to exhibit strong growth as the implementation of a free trade agreement (FTA) with the US leads to a tougher stance on similares that should push patients towards legitimate generics.

In December 2007, the Peru-US free trade agreement was finally signed by US President George Bush and Peruvian President Alan Garcia following its ratification by the US Congress in the previous month. Although the wording of the intellectual property (IP) right provisions in the bill were watered-down under pressure from the Democrat-controlled US Congress, the agreement should still allow the vast majority of US exports duty-free access to Peru. Consequently, it is the US generics industry that has made the most positive noises concerning the bill. Overall trade between the two countries reached US$9bn in 2006.

For Q108, BMI has overhauled its Business Environment Ratings methodology. Under the new system, Peru is ranked last in the Americas regions on 39 points, just one point behind Venezuela. The small size of the drug market and unspectacular growth forecast serve to limit the potential returns. However, in terms of risk, the market is mid-ranking in the region due to an improving regulatory environment and stable political and economic environment.

The government's 2008 budget, published in August, pledges a 28% increase in overall investment, with social services seeing steep rises. Higher tax revenues and a booming economy should allow continuing record budget surpluses. This should help Garcia push forward increased coverage under the unified and strengthened Seguro Integral de Salud (SIS) health insurance system. The key will be ensuring those newly enrolled in the scheme can actually access health services and obtain basic medicine. Opposition parties are questioning the view that Garcia handled the August 2007 earthquake and resulting health crisis admirably, citing HIV-infected blood transfusions and irregular health purchases that could see citizens returning to street protests.

Contents:

Executive Summary

Peru: Pharmaceuticals and Healthcare Industry SWOT

Peru Political SWOT Analysis

Peru Economic SWOT Analysis

Peru Business Environment SWOT Analysis

Business Environment Ranking

Pharmaceutical Ratings - Revised Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Component

Peru - Business Environment Ranking

Table: Pharmaceutical Business Environment Rankings

Limits To Potential Returns

Risks To Realisation Of Returns

Peru - Market Summary

Regulatory Regime

Intellectual Property Regime

Pricing And Reimbursement Issues

Other Regulatory Issues

Industry Developments

Healthcare Sector

Pharmaceutical Sector

Industry Forecast Sce

Overall Market Forecast

Table: Peru Drug Market Indicators, 2006-2012

Key Growth Factors - Industry

Table: Health Expenditure Indicators

Key Growth Factors - Macroeconomic

Table: Peru - Economic Activity

Prescription Market Forecast

Table: Prescription Market Indicators (US$mn unless otherwise stated)

OTC Market Forecast

Table: OTC Market Indicators (US$mn unless otherwise stated)

Generics Market Forecast

Table: Generic Market Indicators

Export/Import Forecasts

Table: Import/Export Trends (US$mn)

Other Healthcare Data Forecasts

Table: Other Healthcare Data Forecasts

Key Risks to BMI's Forecast Scenario

Competitive Landscape

Peru Pharmaceuticals & Healthcare Report Q1 2008

Table: Peruvian Pharmaceutical Companies That Acquired GMP Accreditation In 2006

Company Profiles

Leading Multinationals

Sanofi-Aventis

Merck & Co

GlaxoSmithKline

Novartis

Pfizer

Indigenous Manufacturer Profiles

Farmaindustria

Unimed

Our Forecast Modelling

How We Generate Our Industry Forecasts

Pharmaceutical Industry

Sources

For more information visit www.researchandmarkets.com/reports/c86315

Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com